Naim Alkhouri, MD

Naim Alkhouri, MD, FAASLD, DABOM, is the chief of transplant hepatology and director of the Steatotic Liver Program at Arizona Liver Health.

Articles by Naim Alkhouri, MD

Semaglutide Shows Promise for MASH Resolution, Severe Fibrosis: Naim Alkhouri, MD

ByKyle Munz,Naim Alkhouri, MD

May 9th 2025

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH) and severe fibrosis.

Early Identification of MASLD/MASH Saves Lives: Naim Alkhouri, MD

ByKyle Munz,Naim Alkhouri, MD

May 6th 2025

Lacking awareness of metabolic dysfunction-associated steatohepatitis (MASH) constitutes a critical barrier for enhancing patient care, said Naim Alkhouri, MD. Awareness efforts can not only increase patient access, but also improve the overall wellbeing, experience, and outcomes for this population.

Increased Awareness, Novel Interventions Spell New Era for MASLD/MASH: Naim Alkhouri, MD

ByKyle Munz,Naim Alkhouri, MD

April 24th 2025

The future of treating metabolic dysfunction–associated steatohepatitis (MASH) looks brighter than ever, says Naim Alkhouri, MD, as data emerges on newly developed interventions.

New Hope and Persistent Challenges for MASH Treatment: Naim Alkhouri, MD

ByKyle Munz,Naim Alkhouri, MD

April 17th 2025

Recent advances have marked a turning point for the treatment noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), with more therapies on the horizon to hopefully better address patients' cirrhosis, explained Naim Alkhouri, MD.

Naim Alkhouri, MD

Articles by Naim Alkhouri, MD

Semaglutide Shows Promise for MASH Resolution, Severe Fibrosis: Naim Alkhouri, MD

Early Identification of MASLD/MASH Saves Lives: Naim Alkhouri, MD

Increased Awareness, Novel Interventions Spell New Era for MASLD/MASH: Naim Alkhouri, MD

New Hope and Persistent Challenges for MASH Treatment: Naim Alkhouri, MD

Latest Updated Articles

Trending on AJMC

FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301

Sudden Death in HFpEF Often Preceded by Clinical Decline

How Often Do Health Insurers Deny Doctor-Recommended Care?

New Data Support Pimicotinib as Durable for Rare Tenosynovial Giant Cell Tumor

Acoramidis Shows Durable Benefit at 54 Months in ATTR-CM